JP2023027066A5 - - Google Patents

Download PDF

Info

Publication number
JP2023027066A5
JP2023027066A5 JP2022182194A JP2022182194A JP2023027066A5 JP 2023027066 A5 JP2023027066 A5 JP 2023027066A5 JP 2022182194 A JP2022182194 A JP 2022182194A JP 2022182194 A JP2022182194 A JP 2022182194A JP 2023027066 A5 JP2023027066 A5 JP 2023027066A5
Authority
JP
Japan
Prior art keywords
crystalline
preparing
powder
compound
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022182194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023027066A (ja
Filing date
Publication date
Priority claimed from JP2020504160A external-priority patent/JP7179049B2/ja
Application filed filed Critical
Publication of JP2023027066A publication Critical patent/JP2023027066A/ja
Publication of JP2023027066A5 publication Critical patent/JP2023027066A5/ja
Pending legal-status Critical Current

Links

JP2022182194A 2017-08-01 2022-11-15 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 Pending JP2023027066A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710648135 2017-08-01
CN201710648135.2 2017-08-01
JP2020504160A JP7179049B2 (ja) 2017-08-01 2018-07-31 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
PCT/CN2018/097797 WO2019024845A1 (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020504160A Division JP7179049B2 (ja) 2017-08-01 2018-07-31 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途

Publications (2)

Publication Number Publication Date
JP2023027066A JP2023027066A (ja) 2023-03-01
JP2023027066A5 true JP2023027066A5 (cg-RX-API-DMAC7.html) 2023-08-01

Family

ID=65233118

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020504160A Active JP7179049B2 (ja) 2017-08-01 2018-07-31 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
JP2022182194A Pending JP2023027066A (ja) 2017-08-01 2022-11-15 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020504160A Active JP7179049B2 (ja) 2017-08-01 2018-07-31 オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途

Country Status (4)

Country Link
US (1) US10759779B2 (cg-RX-API-DMAC7.html)
JP (2) JP7179049B2 (cg-RX-API-DMAC7.html)
CN (2) CN115710250A (cg-RX-API-DMAC7.html)
WO (1) WO2019024845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
MX2021012833A (es) * 2019-05-15 2021-11-25 Eisai R&D Man Co Ltd Metodo y compuesto utiles en la preparacion del antagonista del receptor de orexina-2 y lemborexant que tiene pocas impurezas.
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
KR20220061950A (ko) * 2019-09-13 2022-05-13 에자이 알앤드디 매니지먼트 가부시키가이샤 불면증을 치료하기 위한 약제학적 조성물
JP2023506025A (ja) 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス.アール.オー. レンボレキサントの固体形態
IL328515A (en) * 2020-01-16 2026-07-01 Eisai R&D Man Co Ltd Lamborxant drug substance and medical preparation containing it
WO2023007320A1 (en) * 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN119285556B (zh) * 2024-12-13 2025-02-28 四川健林药业有限责任公司 莱博雷生中间体的合成纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) * 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US9416109B2 (en) * 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
CN104592184B (zh) 2014-12-15 2017-09-29 云南省药物研究所 灯盏乙素苷元晶型及其制备方法
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途

Similar Documents

Publication Publication Date Title
JP2023002516A5 (cg-RX-API-DMAC7.html)
JP2021028338A5 (cg-RX-API-DMAC7.html)
JP2023036708A5 (cg-RX-API-DMAC7.html)
JP2024071370A5 (cg-RX-API-DMAC7.html)
JP2023553930A5 (cg-RX-API-DMAC7.html)
JP2021536511A5 (cg-RX-API-DMAC7.html)
JP2011506330A5 (cg-RX-API-DMAC7.html)
JP2021535111A5 (cg-RX-API-DMAC7.html)
JP2009535340A5 (cg-RX-API-DMAC7.html)
JP2004526788A5 (cg-RX-API-DMAC7.html)
JP2012516344A5 (cg-RX-API-DMAC7.html)
JP2018168191A5 (cg-RX-API-DMAC7.html)
JP2023109937A5 (cg-RX-API-DMAC7.html)
HRP20250770T1 (hr) Derivati triazina koji imaju inhibirajuće djelovanje na replikaciju virusa i farmaceutski pripravak koji ih sadrži
JP2010132669A (ja) ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物
JP2014530818A5 (cg-RX-API-DMAC7.html)
JP2020528913A5 (cg-RX-API-DMAC7.html)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
JP2015522037A5 (cg-RX-API-DMAC7.html)
JP2025508071A5 (cg-RX-API-DMAC7.html)
JPWO2021033729A5 (cg-RX-API-DMAC7.html)
JP2025516683A5 (cg-RX-API-DMAC7.html)
JP2025502300A5 (cg-RX-API-DMAC7.html)
JP2020138960A5 (cg-RX-API-DMAC7.html)
JP2022500445A5 (cg-RX-API-DMAC7.html)